Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cystic Fibrosis Buyers’ Club

- PMLiVE

Orkambi buyers’ club set up to gain access to cheaper versions

Legal to import generics from abroad

- PMLiVE

Vertex makes choice for all-important CF triple therapy

Promises to treat up to 90% of CF patients

- PMLiVE

NHS England wants money-back guarantee on Orkambi

Vertex resisting real-world data proposal

- PMLiVE

Still no breakthrough on Orkambi talks, MPs want answers

As other price deals go through, Orkambi stalled again

Vertex: a vision of treating all CF patients worldwide draws closer

Its high prices are controversial, but Vertex also embodies the best of biopharma drug development

The Orkambi row explained

Q&A and timeline

- PMLiVE

The Orkambi blame game

Grilling by MPs sheds some light on long-running row over CF drug

- PMLiVE

#OrkambiNow?

After a long standoff over CF treatment Orkambi, is a deal imminent?

- PMLiVE

Setback for Vertex’s cystic fibrosis challenger Proteostasis

Unlikely to match market leader's triple therapy

- PMLiVE

Is Orkambi deal close? Vertex meets again today with NHS England

Campaigners hopes rise after three year wait

- PMLiVE

Optimism on Orkambi in England as talks to resume

Scotland's deal puts pressure on NHS England and NICE

- PMLiVE

Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

NHS England going public with price makes deal impossible, says Leiden

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links